GLP-1 / Weight Management
Incretin-based peptides and metabolic research compounds including GLP-1, dual, and triple receptor agonists for glucose and weight regulation studies.
14 products available
Up to 50% OffSemaglutide
Clinically studied for steady weight reduction — once weekly
Up to 60% OffTirzepatide
The most studied dual-agonist for weight reduction
Up to 78% OffRetatrutide
Triple-receptor agonist studied for enhanced metabolic activity
Up to 38% OffLiraglutide
Daily GLP-1 studied for steady appetite regulation
Up to 13% OffCagrilintide
Studied for amylin-mediated satiety pathways beyond GLP-1
Cagrisema (2.5mg + 2.5mg)
Dual amylin/calcitonin agonist studied for satiety research
Retatrutide 20mg + Tirzepatide 40mg
Studied for maximum metabolic receptor coverage
Survodutide
Studied for hepatic fat reduction and weight management
Mazdutide
Dual-agonist studied for weight and liver fat reduction
Dulaglutide
The most-prescribed GLP-1 with cardiovascular data
Up to 41% OffAOD9604
Studied for selective fat metabolism without GH axis activation
SLU-PP-322
Exercise-mimetic peptide studied for cellular fat metabolism
Adipotide/FTTP
Studied for adipose tissue vascular modulation
FTPP Adipotide
Studied for targeted adipose vasculature disruption
